ClinicalTrials.gg
Active, not recruitingNCT04938167POST-ITUpdated Apr 8, 2026

Preductal Oxygen Saturation Target in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure or Pulmonary Hypertension

An interventional study of 95% - 99% SpO2 target in Persistent Pulmonary Hypertension of the Newborn and Hypoxemic Respiratory Failure, sponsored by University of California, Davis. Active, not recruiting at 1 site in United States. Open to participants aged 0 Days to 28 Days. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by University of California, Davis · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
0 Days to 28 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States — 1 open to participants now, 2 under way, none of them phase 3. Persistent Fetal Circulation Syndrome · United States.

Enrollment
5th of 12
54 · median 38
Started
2021
the only one that year
No phase
2 of 16
none open now
Registered
16th of 16
by date
Lead sponsor
1 of 16
University of California, Davis

Among the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, this one is the 5th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2021, is one of 2 with no phase, and was the 16th registered.

Persistent Fetal Circulation Syndrome

40 studies on the registry are indexed under Persistent Fetal Circulation Syndrome; 6 are open to participants now.

Browse Persistent Fetal Circulation Syndrome studies →

Open to participants now

1 of the 16 studies in Persistent Fetal Circulation Syndrome with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Persistent Fetal Circulation Syndrome studies recruiting now, 2 set no upper age limit and 3 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 0 Days to 28 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Persistent Fetal Circulation Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to evaluate two oxygen saturation goals for newborns with pulmonary hypertension. Participation in this research will involve random assignment to one of two oxygen saturation goals, review of the medical record and targeted echocardiograms.

Read the detailed description

Successful transition at birth is dependent on establishment of lungs as the organ of gas exchange. Breathing at birth and an increase in alveolar oxygen tension (PAO2) leads to an 8-10 fold increase in pulmonary blood flow with a marked reduction in pulmonary vascular resistance (PVR). Failure to decrease PVR at birth results in hypoxemic respiratory failure (HRF) and persistent pulmonary hypertension of the newborn (PPHN). Hypoxemia exacerbates PPHN by increasing PVR. However, administration of excess oxygen in animal studies has been shown to increase free radical formation and reduce response to pulmonary vasodilators such as inhaled nitric oxide (iNO).

Thus, there is potential for benefit and also poor outcomes at both higher and lower oxygen saturations (SpO2), with the ideal range being unknown. The investigators will conduct a randomized unblinded, pilot trial to compare two ranges of target preductal SpO2 in late preterm and term infants with HRF or PPHN. During this trial the investigators will assess the reliability of a hypoxic respiratory failure/pulmonary hypertension (HRF/PH) score that could then be used in a larger clinical trial. The investigators will also assess trial feasibility and obtain preliminary estimates of outcomes. Our central hypothesis is that neonates with pulmonary hypertension (PH) and/or HRF, targeting preductal SpO2 of 95-99% (intervention) will result in lower PVR and lower need for non-oxygen based pulmonary vasodilators (iNO, milrinone and sildenafil) compared to a target of 91-95% (standard).

03

Conditions studied

  • Persistent Pulmonary Hypertension of the Newborn
  • Hypoxemic Respiratory Failure
04

Who can participate

Ages eligible
0 Days to 28 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Corrected gestational age (postmenstrual age) > 34 6/7 weeks
  • postnatal age ≤ 28 d
  • on respiratory support with invasive mechanical ventilation, non-invasive ventilation, CPAP or high flow nasal cannula (defined as flow rates ≥ 2 LPM with a humidifier), inspired oxygen concentration, FiO2 ≥ 0.3
  • and echocardiography shows any finding suggestive of PH (or score > 0 for PH in table 2).
  • Infants with congenital diaphragmatic hernia (CDH), Down syndrome, hypoxic ischemic encephalopathy (HIE) on therapeutic hypothermia and patent ductus arteriosus (PDA), patent foramen ovale/atrial septal defect (PFO/ASD) and ventricular septal defect (VSD) (single or multiple) \< 2 mm can be included in the study.

Exclusion criteria

Exclusion Criteria:

  • \< 32 weeks gestation at birth (31 6/7 or lower)
  • Weight \< 2000 g at the time of enrollment
  • Severe HRF with OI > 35 or SpO2 \< 75% on FiO2 = 1.0 on mechanical ventilation for > 60 minutes in spite of correction of reversible factors such as pneumothorax
  • A condition or congenital anomaly known to be lethal (high likelihood of death during infancy) - e.g., trisomy 18 or trisomy 13
  • Congenital heart disease other than ASD/PFO, PDA or VSD (single or multiple defects) \< 2 mm.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • No intervention
    Standard arm

    target preductal SpO2 - 91 to 95%

  • Experimental
    Intervention arm

    target preductal SpO2 - 95 to 99%

    Other: 95% - 99% SpO2 target

Interventions

  • Other95% - 99% SpO2 target

    If the infant is randomized to the intervention arm, the oxygen saturation goal will be changed from the standard goal of 91% - 95% to the experimental goal of 95%-99%. The treating medical team will then adjust the oxygen and respiratory support to maintain these goals (SpO2 alarm levels will be set at 93% and 100%).

06

What researchers measure

Primary outcomes

  1. Hypoxemic Respiratory Failure and Pulmonary Hypertension (HRF/PH) score

    Most randomized trials evaluating PPHN have taken oxygenation, echocardiographic evidence of PH or survival with extracorporeal membrane oxygenation (ECMO) as primary endpoints. Oxygenation was primarily assessed with postductal arterial gases. More recently, preductal SpO2 and blood gases have been shown to have advantages during management of PPHN with congenital diaphragmatic hernia (CDH). Given the low need for ECMO in PPHN (other than due to CDH), the investigators have developed a HRF/PH score combining oxygenation using preductal SpO2 and echocardiographic parameters. The score ranges from 0 to 15, with a higher score corresponding to worse respiratory failure or pulmonary hypertension. The primary aim of this pilot trial to understand the variation of this score at two oxygen saturation targets and assess its reliability and validity.

    Time frame: At enrollment

  2. Correlation of the Oxygenation and Echocardiography components of the HRF/PH scores

    Time frame: At enrollment

Secondary outcomes

  1. Intracluster correlation coefficients of the HRF/PH score

    The investigators will fit a sequence of two-level multilevel models to estimate intracluster correlation coefficients based on the between-infant (level 2) and other relevant variance component(s), after adjusting for fixed effects, including study arm and sex. Interrater reliability at specific days will be estimated by having two or more raters (level 1) score each infant's underlying oxygenation and echocardiography measurements, while within-infant, over-time intracluster correlation will be estimated by analyzing a data set with one score per infant per day (level 1), with fixed effects added to account for day effects and possibly restricted to a smaller number of the later days (e.g. days 3 to 7), in case early-day values are grossly unstable.

    Time frame: Days 3-7

  2. Preliminary estimates of intervention effects on outcomes (length of stay, duration of mechanical ventilation, and ECMO)

    For obtaining preliminary estimates of intervention effects on Day-7 HRF/PH, the investigators will use the results of Outcome 1 to inform our choice of how best to account for the baseline HRF/PH score, although the investigators anticipate that the within-infant correlation will be suitably modest that ANCOVA-like approaches will be preferred over differences-in-differences. Intervention effects and other regression-parameters will be estimated with robust 95% confidence intervals, to ensure accurate coverage.

    Time frame: Day 7

07

Study locations

1 site
08

References and documents

Publications

  • Siefkes H, Sunderji S, Vaughn J, Sankaran D, Vali P, Vadlaputi P, Timberline S, Bhatt A, Tancredi D, Lakshminrusimha S. Factors to Consider to Study Preductal Oxygen Saturation Targets in Neonatal Pulmonary Hypertension. Children (Basel). 2022 Mar 11;9(3):396. doi: 10.3390/children9030396. PubMed 35327768 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2021 to primary completion in Dec 2024, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Jun 24, 2021
StartActual
Aug 1, 2021
Primary completionActual
Dec 31, 2024
CompletionEst.
Dec 31, 2026
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04938167
Responsible party
Sponsor
First posted
Jun 24, 2021
Start date
Aug 1, 2021
Primary completion
Dec 31, 2024
Completion
Dec 31, 2026 (estimated)
Last update
Apr 8, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion